Literature DB >> 24638276

Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study.

L J Anderson1, W Henley, K M Wyatt, V Nikolaou, S Waldek, D A Hughes, G M Pastores, S Logan.   

Abstract

OBJECTIVES: To determine the effectiveness of enzyme replacement therapies (ERT) for children with Gaucher disease (GD).
DESIGN: A longitudinal cohort study including prospective and retrospective clinical data. Age- and gender-adjusted treatment effects were estimated using generalised linear mixed models. Children on treatment contributed data before and during treatment. Children not on treatment contributed natural history data. PARTICIPANTS: Consenting children (N = 25, aged 1.1 to 15.6 years) with a diagnosis of GD (14 with GD1 and 11 with GD3) who attended a specialist treatment centre in England. At recruitment, 24 patients were receiving ERT (mean treatment duration, 5.57 years; range 0-13.7 years). OUTCOME MEASURES: Clinical outcomes chosen to reflect disease progression, included platelet count; haemoglobin and absence/presence of bone pain.
RESULTS: Duration of ERT was associated with statistically significant improvements in platelet count (p < 0.001), haemoglobin (p < 0.001), and reported bone pain (p = 0.02). The magnitude of effect on haematological parameters was greater in children with GD3 than in those with GD1.
CONCLUSIONS: These data provide further evidence of the long-term effectiveness of ERT in children with GD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24638276     DOI: 10.1007/s10545-014-9693-8

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  27 in total

1.  Evaluation of Gaucher disease using magnetic resonance imaging.

Authors:  D I Rosenthal; J A Scott; J Barranger; H J Mankin; S Saini; T J Brady; L K Osier; S Doppelt
Journal:  J Bone Joint Surg Am       Date:  1986-07       Impact factor: 5.284

2.  Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.

Authors:  Richard J Wenstrup; Katherine A Kacena; Paige Kaplan; Gregory M Pastores; Ainu Prakash-Cheng; Ari Zimran; Thomas N Hangartner
Journal:  J Bone Miner Res       Date:  2007-01       Impact factor: 6.741

3.  Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction.

Authors:  Deborah Elstein; A Joseph Foldes; David Zahrieh; Gabriel M Cohn; Maja Djordjevic; Costin Brutaru; Ari Zimran
Journal:  Blood Cells Mol Dis       Date:  2011-05-04       Impact factor: 3.039

4.  Gaucher disease and parkinsonism: a phenotypic and genotypic characterization.

Authors:  N Tayebi; M Callahan; V Madike; B K Stubblefield; E Orvisky; D Krasnewich; J J Fillano; E Sidransky
Journal:  Mol Genet Metab       Date:  2001-08       Impact factor: 4.797

Review 5.  Bone and joint complications related to Gaucher disease.

Authors:  G M Pastores; M J Patel; H Firooznia
Journal:  Curr Rheumatol Rep       Date:  2000-04       Impact factor: 4.592

6.  Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study.

Authors:  Marieke Biegstraaten; Eugen Mengel; Laszlo Maródi; Milan Petakov; Claus Niederau; Pilar Giraldo; Derralyn Hughes; Mirando Mrsic; Atul Mehta; Carla E M Hollak; Ivo N van Schaik
Journal:  Brain       Date:  2010-08-07       Impact factor: 13.501

7.  Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.

Authors:  Hans Andersson; Paige Kaplan; Katherine Kacena; John Yee
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

8.  The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.

Authors:  K Wyatt; W Henley; L Anderson; R Anderson; V Nikolaou; K Stein; L Klinger; D Hughes; S Waldek; R Lachmann; A Mehta; A Vellodi; S Logan
Journal:  Health Technol Assess       Date:  2012       Impact factor: 4.014

9.  THE METABOLISM OF GLUCOCEREBROSIDES. I. PURIFICATION AND PROPERTIES OF A GLUCOCEREBROSIDE-CLEAVING ENZYME FROM SPLEEN TISSUE.

Authors:  R O BRADY; J KANFER; D SHAPIRO
Journal:  J Biol Chem       Date:  1965-01       Impact factor: 5.157

10.  Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy.

Authors:  Raphael Schiffmann; Henry Mankin; James M Dambrosia; Ramnik J Xavier; Constance Kreps; Suvimol C Hill; Norman W Barton; Daniel I Rosenthal
Journal:  Blood Cells Mol Dis       Date:  2002 Mar-Apr       Impact factor: 3.039

View more
  3 in total

1.  Rare Case of Hepatic Gaucheroma in a Child on Enzyme Replacement Therapy.

Authors:  Sophy Korula; Penny Owens; Amanda Charlton; Kaustuv Bhattacharya
Journal:  JIMD Rep       Date:  2016-06-23

2.  Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.

Authors:  Marcio Andrade-Campos; Pilar Alfonso; Pilar Irun; Judith Armstrong; Carmen Calvo; Jaime Dalmau; Maria-Rosario Domingo; Jose-Luis Barbera; Horacio Cano; Maria-Angeles Fernandez-Galán; Rafael Franco; Inmaculada Gracia; Miguel Gracia-Antequera; Angela Ibañez; Francisco Lendinez; Marcos Madruga; Elena Martin-Hernández; Maria Del Mar O'Callaghan; Alberto Pérez Del Soto; Yolanda Ruiz Del Prado; Ignacio Sancho-Val; Pablo Sanjurjo; Miguel Pocovi; Pilar Giraldo
Journal:  Orphanet J Rare Dis       Date:  2017-05-03       Impact factor: 4.123

3.  A new framework for evaluating the health impacts of treatment for Gaucher disease type 1.

Authors:  Michael L Ganz; Sean Stern; Alex Ward; Luba Nalysnyk; Martin Selzer; Alaa Hamed; Neal Weinreb
Journal:  Orphanet J Rare Dis       Date:  2017-02-20       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.